Provided by Tiger Trade Technology Pte. Ltd.

Aileron Therapeutics Inc

2.11
0.0000
Volume:- -
Turnover:131.69K
Market Cap:45.72M
PE:-0.99
High:2.11
Open:2.11
Low:2.11
Close:2.11
52wk High:7.42
52wk Low:1.61
Shares:21.67M
Float Shares:19.42M
Volume Ratio:- -
T/O Rate:- -
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.1331
EPS(LYR):-3.4210
ROE:-54.95%
ROA:-31.63%
PB:0.91
PE(LYR):-0.62

Loading ...

Aileron Therapeutics Changes Name to Rein Therapeutics

MT Newswires Live
·
Jan 11, 2025

BRIEF-Aileron Therapeutics Announces Rebranding To Rein Therapeutics

Reuters
·
Jan 11, 2025

Aileron Therapeutics Announces Rebranding to Rein Therapeutics

THOMSON REUTERS
·
Jan 11, 2025

Aileron Therapeutics : Co's Shares to Begin Trading on Nasdaq Under Trading Symbol "Rntx" Effective Jan 13

THOMSON REUTERS
·
Jan 11, 2025

Aileron Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary

Reuters
·
Nov 15, 2024

Aileron Therapeutics Q3 EPS $(0.27) Beats $(0.41) Estimate

Benzinga
·
Nov 15, 2024

Aileron Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

THOMSON REUTERS
·
Nov 15, 2024

Aileron Therapeutics, Inc. Q3 Basic EPS USD -0.27

THOMSON REUTERS
·
Nov 15, 2024

BRIEF-Aileron Therapeutics Announces Positive Topline Data From Cohort 2 Of The Phase 1B Clinical Trial Of LTI-03 In Idiopathic Pulmonary Fibrosis

Reuters
·
Nov 13, 2024

Aileron Therapeutics Announces Positive Topline Data From Cohort 2 of the Phase 1B Clinical Trial of Lti-03 in Idiopathic Pulmonary Fibrosis (Ipf)

THOMSON REUTERS
·
Nov 13, 2024

Aileron Therapeutics Inc - High-Dose Lti-03 Reduces Expression of Profibrotic Proteins

THOMSON REUTERS
·
Nov 13, 2024

Aileron Therapeutics Inc expected to post a loss of 41 cents a share - Earnings Preview

Reuters
·
Nov 09, 2024

Aileron Therapeutics Inc expected to post a loss of 41 cents a share - Earnings Preview

Reuters
·
Nov 02, 2024

BRIEF-Aileron Therapeutics And Advancium Health Network Announce An Exclusive Option Agreement For The Acquisition Of ALRN-6924 For Retinoblastoma

Reuters
·
Oct 31, 2024

Aileron Therapeutics and Advancium Health Network Announce an Exclusive Option Agreement for the Acquisition of Alrn-6924 for Retinoblastoma

THOMSON REUTERS
·
Oct 31, 2024

Aileron Therapeutics Inc expected to post a loss of 41 cents a share - Earnings Preview

Reuters
·
Oct 27, 2024